Key result
Opakalim potentiates in vitro activity of Kv7.2/7.3 channels carrying the DEE-causing G281E mutation.
Why the study?
Does opakalim potentiate the activity of Kv7.2/7.3 channels containing a DEE-causing mutation in vitro?
Does opakalim potentiate the activity of Kv7.2/7.3 channels containing a DEE-causing mutation in vitro?
Opakalim (BHV-7000) is being assessed for its in vitro activity on Kv7.2/7.3 channels with a DEE-causing mutation.
Authors
No takes yet. Share an insight, caveat, or question.
Opakalim merits evaluation in G281E-related DEE; leaves open clinical translation pending in vivo and human studies.
Spitznagel et al. (2026) studied this question. Opakalim (BHV-7000) potentiates the in vitro activity of Kv7.2/7.3 channels containing a single copy of the Kv7.2 DEE-causing mutation G281E.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: